In search of the mechanisms that promote tumourigenic ErbB signalling, we have previously demonstrated that unlike NSCLC, pancreatic cancer cells lack activating EGFR mutations (Tzeng et al, 2007a). The gene discussed is EGFR; the disease is pancreatic neoplasm.